Seelos announces final data from phase i pk/pd study of intranasal racemic ketamine

Seelos therapeutics announces final data from phase i pk/pd study of intranasal racemic ketamine (sls-002) and clinical development plans.seelos therapeutics inc - sls-002 was safe and well tolerated across all doses.seelos therapeutics - fda feedback from type c meeting supported design of a 16 day study for acute suicidal ideation and behavior.
SEEL Ratings Summary
SEEL Quant Ranking